electroCore, Inc.

ECOR

US28531P2020

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
6.4 ^USD	+3.06%		+0.16%	+7.53%

Jul. 01	ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell 3000E Index	CI
Jul. 01	ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell Microcap Index	CI

ElectroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

August 04, 2022 at 04:05 pm EDT

electroCore, Inc. provided revenue guidance for the third quarter of 2022. FOr the quarter, the company expected net revenue to be approximately second quarter 2022 levels.

Latest news about electroCore, Inc.

ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell 3000E Index	Jun. 30	CI
ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell Microcap Index	Jun. 30	CI
ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell Microcap Growth Index	Jun. 30	CI
ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell 3000E Growth Index	Jun. 30	CI
ElectroCore Announces the Commercial Launch of TAC-STIM??	Jun. 25	CI
ElectroCore, Inc. announced that it has received $2.817568 million in funding	Jun. 04	CI
ElectroCore, Inc. announced that it expects to receive $2.817568 million in funding	May. 30	CI
Transcript : ElectroCore, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (ECOR) ELECTROCORE Posts Q1 Revenue $5.4M, vs. Street Est of $4.8M	May. 08	MT
ElectroCore, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
ElectroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance	May. 03	CI
ElectroCore, Inc. Announces Results of Truvaga Plus Consumer Study	Apr. 30	CI
ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness	Apr. 08	CI
ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Transcript : ElectroCore, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
ElectroCore, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 13	CI
Earnings Flash (ECOR) ELECTROCORE Posts Q4 Revenue $5.2M, vs. Street Est of $5M	Mar. 13	MT
Certain Common Stock of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Certain Warrants of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Certain Options of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
HC Wainwright Adjusts electroCore Price Target to $15 From $11, Maintains Buy Rating	Jan. 22	MT
Ondine Biomedical appoints Joseph Errico as new CFO	Jan. 16	AN
ElectroCore Says Two US Patents Issued for Non-Invasive Vagus Nerve Stimulation Technology	Dec. 26	MT
ElectroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board	Dec. 14	CI
Transcript : ElectroCore, Inc. - Analyst/Investor Day	Nov. 21

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for electroCore, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.4 USD

Average target price

23.16 USD

Spread / Average Target

+261.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
ELECTROCORE, INC.	+7.53%	41.24M
SHOCKWAVE MEDICAL	+75.69%	12.57B
PENUMBRA, INC.	-24.14%	7.4B
MASIMO CORPORATION	-4.48%	5.95B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+5.70%	5.05B
GETINGE AB	-14.67%	4.95B
APT MEDICAL INC.	+19.72%	4.29B
INARI MEDICAL, INC.	-16.19%	3.16B
SKAN GROUP AG	-0.87%	2.01B
NOVOCURE LIMITED	+20.43%	1.93B

Medical Equipment

electroCore, Inc.

Equities

ECOR

US28531P2020

Medical Equipment, Supplies & Distribution

ElectroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Latest news about electroCore, Inc.

Chart electroCore, Inc.

Company Profile

Income Statement Evolution

Ratings for electroCore, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Equipment